Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis
Kazuya Ishiguro, Hiroshi Kitajima, Takeshi Niinuma, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis
Raymond Chen, Charles A. Ishak, Daniel D. De Carvalho
Cancer Discovery (2021) Vol. 11, Iss. 11, pp. 2707-2725
Open Access | Times Cited: 129
Targeting EZH2 for cancer therapy: From current progress to novel strategies
Jia Zeng, Jifa Zhang, Ying Sun, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114419-114419
Closed Access | Times Cited: 68
Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective
Ming Jin, Kwang Won Jeong
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 7, pp. 1333-1347
Open Access | Times Cited: 32
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Pavlina Spiliopoulou, Sarah Spear, Hasan Mirza, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 4, pp. 522-534
Open Access | Times Cited: 32
Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies
Deping Li, Xiaopeng Peng, Zhihao Hu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115982-115982
Closed Access | Times Cited: 18
A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: from molecular interactions to potential therapeutic targets
Mina Alimohammadi, Payman Rahimzadeh, Ramin Khorrami, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155401-155401
Closed Access | Times Cited: 8
Endogenous Retroviruses (ERVs): Does RLR (RIG-I-Like Receptors)-MAVS Pathway Directly Control Senescence and Aging as a Consequence of ERV De-Repression?
Eros Di Giorgio, Luigi E. Xodo
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Recent advances in EZH2-based dual inhibitors in the treatment of cancers
Xiaojuan Yang, Xu Lu, Yang Li
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115461-115461
Closed Access | Times Cited: 13
Emerging role of G9a in cancer stemness and promises as a therapeutic target
Joshua R. Haebe, Christopher J. Bergin, Tamara Sandouka, et al.
Oncogenesis (2021) Vol. 10, Iss. 11
Open Access | Times Cited: 29
Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development
Ye Jin, Tianjia Liu, Haoming Luo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 20
Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor
Yajie Shi, Qiuyue Zhang, Maoying Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 8, pp. 5685-5702
Closed Access | Times Cited: 13
G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma
Maxine Lam, Jose Antonio Reales‐Calderón, Jin Rong Ow, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
Rui Liu, Zongwei Li, Rui Chen, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Small molecule compounds targeting G9a/GLP: Recent advances and perspectives
Qiangsheng Zhang, Li Lu, Siyan Li, et al.
European Journal of Medicinal Chemistry (2025), pp. 117525-117525
Closed Access
PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing
Ka-wing Fong, Jonathan C. Zhao, Xiaodong Lü, et al.
Molecular Cell (2022) Vol. 82, Iss. 24, pp. 4611-4626.e7
Open Access | Times Cited: 17
Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
Jing-Zan Zhang, Lin Zhang, Xin Ding, et al.
European Journal of Medicinal Chemistry (2025) Vol. 285, pp. 117240-117240
Closed Access
G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials
Aina Bellver‐Sanchís, Marta Ribalta‐Vilella, Alba Irisarri, et al.
Medicinal Research Reviews (2025)
Open Access
Short-term and long-term high-fat diet promote metabolic disorder through reprogramming mRNA m6A in white adipose tissue by gut microbiota
Youhua Liu, Jiaqi Liu, Ruiti Ren, et al.
Microbiome (2025) Vol. 13, Iss. 1
Open Access
Decoding DNA methylation in epigenetics of multiple myeloma
Ting Yang, Xiaobo Liu, Shaji Kumar, et al.
Blood Reviews (2021) Vol. 51, pp. 100872-100872
Closed Access | Times Cited: 22
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Nor Hayati Ismail, Ali Mussa, Nur Atikah Zakaria, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2767-2767
Open Access | Times Cited: 15
Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer
Dexter Kai Hao Thng, Lissa Hooi, Clarissa Chin Min Toh, et al.
Molecular Oncology (2023) Vol. 17, Iss. 11, pp. 2275-2294
Open Access | Times Cited: 9
C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma
Coty Hing Yau Cheung, Chi‐Keung Cheng, Kam Tong Leung, et al.
Blood Advances (2024) Vol. 8, Iss. 9, pp. 2217-2234
Open Access | Times Cited: 3
Histone Methylation Related Therapeutic Challenge in Cardiovascular Diseases
Yang Yang, Ying Luan, Ruixia Yuan, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 19
Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy
Yihui Zhou, Xiaomeng Gao, Yuan Meng, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 19
MYC inhibitors in multiple myeloma
Sandra Martínez-Martín, Laura Soucek
Cancer Drug Resistance (2021)
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top